Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 124
Filter
1.
Diabetes Metab ; 35(5): 410-7, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19815443

ABSTRACT

AIM: Binding of advanced glycation end-products (AGEs) to the receptor for AGEs (RAGE) contributes to diabetic vascular complications. RAGE transcript splicing generates membrane-bound proteins [full-length (FL) and N-truncated (Nt)] and a soluble protein [endogenous secretory (esRAGE)] that may act as a decoy. We tested the effect of AGE-ligands on the regulation of RAGE isoforms and the consequences on red blood cell (RBC) adhesion. METHODS: RAGE isoforms were measured by real-time RT-PCR assay, using a LightCycler System, in human umbilical vein endothelial cells (HUVECs), incubated with either characterized AGEs [Nvarepsilon-(carboxymethyl)lysine human serum albumin (CML-HSA) and methylglyoxal-modified HSA (MG-HSA)] or with RBCs from diabetic patients (DRBCs). Inhibition of RAGE access was achieved by using blocking either anti-RAGE antibodies or recombinant RAGE. Adhesion of DRBCs to endothelium was measured under flow conditions using HUVECs stimulated with MG-HSA or CML-HSA. Antibodies directed to RBC membrane proteins were tested for blocking DRBC adhesion in static conditions. RESULTS: MG-HSA stimulated the expression of membrane-bound RAGE (FL+Nt) and esRAGE transcripts to similar extents, while CML-HSA and DRBC more selectively induced mRNA for FL and Nt-RAGE. Anti-RAGE antibody inhibited the effect of glycated proteins. Stimulation of HUVECs with CML-HSA enhanced DRBC adhesion, while MG-HSA had no effect. CD233 (band 3) was glycated in DRBC membrane, and anti-CD233 antibodies inhibited the adhesion of DRBCs, as did the anti-RAGE and anti-AGE antibodies. CONCLUSIONS: Receptor engagement by distinct AGEs differentially enhances expression of RAGE isoforms and DRBC adhesion. The CML-adduct, by facilitating adhesion, has more deleterious effects than MG-derived AGEs.


Subject(s)
Erythrocytes/metabolism , Gene Expression Regulation , Glycation End Products, Advanced/metabolism , Receptors, Immunologic/metabolism , Anion Exchange Protein 1, Erythrocyte/chemistry , Anion Exchange Protein 1, Erythrocyte/metabolism , Base Sequence , Binding, Competitive , Cell Adhesion , Cells, Cultured , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/prevention & control , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Erythrocytes/chemistry , Erythrocytes/physiology , Glycated Hemoglobin/analysis , Glycation End Products, Advanced/chemical synthesis , Glycation End Products, Advanced/chemistry , Humans , Ligands , Molecular Sequence Data , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/metabolism , Receptor for Advanced Glycation End Products , Receptors, Immunologic/antagonists & inhibitors , Receptors, Immunologic/chemistry , Receptors, Immunologic/genetics , Sequence Alignment , Serum Albumin/chemistry , Serum Albumin/metabolism
2.
AJNR Am J Neuroradiol ; 28(5): 953-7, 2007 May.
Article in English | MEDLINE | ID: mdl-17494677

ABSTRACT

BACKGROUND AND PURPOSE: Small cerebral vessels are a major site for vascular pathology leading to cerebral infarction and hemorrhage. However, such small cerebral vessels are difficult to visualize by using conventional methods. The goal of our study was the development of methodology allowing visualization of small cerebral arteries in rodents, suitable for experimental models. MATERIALS AND METHODS: Using barium sulfate as a contrast material, we obtained microangiographic images of physiologic and pathologic changes consequent to cerebral infarction in mouse brain by monochromatic synchrotron radiation (SR). To achieve high-resolution and high-contrast images, we used a new x-ray camera with a pixel size of 4.5 microm, and we set the energy level at 37.5 keV, just above the K absorption of barium. RESULTS: Small intracerebral arteries ( approximately 30 microm in diameter) were clearly visualized, as well as the cortical branches (50-70 microm in diameter) at the brain surface. The limit of detection appeared to be vessels approximately 10 microm in diameter. Compared with the noninfarcted side, the number of intracerebral arteries was dramatically decreased in the middle cerebral artery area affected by stroke. CONCLUSIONS: These results indicate the potential of SR for evaluating pathologic changes in small cerebral arteries and for monitoring the impact of pro- and antiangiogenic therapeutic strategies.


Subject(s)
Cerebral Angiography/instrumentation , Cerebral Angiography/methods , Cerebral Arteries/diagnostic imaging , Cerebral Infarction/diagnostic imaging , Synchrotrons , Animals , Barium Sulfate , Cerebrovascular Circulation , Contrast Media , Gamma Cameras , Male , Mice , Mice, SCID , Microcirculation
3.
Curr Drug Targets CNS Neurol Disord ; 4(3): 249-66, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15975028

ABSTRACT

Receptor for advanced glycation endproducts (RAGE), a member of the immunoglobulin superfamily, is a multi-ligand, cell surface receptor expressed by neurons, microglia, astrocytes, cerebral endothelial cells, pericytes, and smooth muscle cells. At least three major types of the RAGE isoforms (full length, C-truncated, and N-truncated) are present in human brains as a result of alternative splicing. Differential expression of each isoform may play a regulatory role in the physiological and pathophysiological functions of RAGE. Analysis of RAGE expression in non-demented and Alzheimer's disease (AD) brains indicated that increases in RAGE protein and percentage of RAGE-expressing microglia paralleled the severity of disease. Ligands for RAGE in AD include amyloid beta peptide (Abeta), S100/calgranulins, advanced glycation endproduct-modified proteins, and amphoterin. Collective evidence from in vitro and in vivo studies supports that RAGE plays multiple roles in the pathogenesis of AD. The major features of RAGE activation in contributing to AD result from its interaction with Abeta, from the positive feedback mechanisms driven by excess amounts of Abeta, and combined with sustained elevated RAGE expression. The adverse consequences of RAGE interaction with Abeta include perturbation of neuronal properties and functions, amplification of glial inflammatory responses, elevation of oxidative stress and amyloidosis, increased Abeta influx at the blood brain barrier and vascular dysfunction, and induction of autoantibodies. In this article, we will review recent advances of RAGE and RAGE activation based on findings from cell cultures, animal models, and human brains. The potential for targeting RAGE mechanisms as therapeutic strategies for AD will be discussed.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Brain/metabolism , Glycation End Products, Advanced/metabolism , Microglia/metabolism , Receptors, Immunologic/metabolism , Alzheimer Disease/immunology , Amyloid beta-Peptides/immunology , Animals , Blood Vessels/cytology , Blood Vessels/immunology , Blood Vessels/metabolism , Blood-Brain Barrier/metabolism , Brain/blood supply , Brain/immunology , Glycation End Products, Advanced/immunology , Humans , Membrane Proteins/immunology , Membrane Proteins/metabolism , Mice , Mice, Transgenic , Microglia/immunology , Pericytes/immunology , Pericytes/metabolism , Protein Isoforms/metabolism , Receptor for Advanced Glycation End Products
4.
Cell Mol Life Sci ; 59(7): 1117-28, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12222959

ABSTRACT

Receptor for AGE (RAGE) is a member of the immunoglobulin superfamily that engages distinct classes of ligands. The biology of RAGE is driven by the settings in which these ligands accumulate, such as diabetes, inflammation, neurodegenerative disorders and tumors. In this review, we discuss the context of each of these classes of ligands, including advance glycation end-products, amyloid beta peptide and the family of beta sheet fibrils, S100/calgranulins and amphoterin. Implications for the role of these ligands interacting with RAGE in homeostasis and disease will be considered.


Subject(s)
Receptors, Immunologic/physiology , Alzheimer Disease/etiology , Amyloidosis/etiology , Animals , Arteriosclerosis/etiology , Arteriosclerosis/metabolism , Arteriosclerosis/pathology , Cell Movement , Chronic Disease , Diabetic Angiopathies/etiology , Diabetic Angiopathies/metabolism , Diabetic Angiopathies/pathology , Homeostasis , Humans , Immunoglobulins/classification , Inflammation/etiology , Mice , Neoplasms/etiology , Neoplasms/pathology , Receptor for Advanced Glycation End Products , Receptors, Immunologic/metabolism , Signal Transduction
5.
Genes Immun ; 3(3): 123-35, 2002 May.
Article in English | MEDLINE | ID: mdl-12070776

ABSTRACT

The receptor for advanced glycation end products (RAGE) and its proinflammatory S100/calgranulin ligands are enriched in joints of subjects with rheumatoid arthritis (RA) and amplify the immune/inflammatory response. In a model of inflammatory arthritis, blockade of RAGE in mice immunized and challenged with bovine type II collagen suppressed clinical and histologic evidence of arthritis, in parallel with diminished levels of TNF-alpha, IL-6, and matrix metalloproteinases (MMP) 3, 9 and 13 in affected tissues. Allelic variation within key domains of RAGE may influence these proinflammatory mechanisms, thereby predisposing individuals to heightened inflammatory responses. A polymorphism of the RAGE gene within the ligand-binding domain of the receptor has been identified, consisting of a glycine to serine change at position 82. Cells bearing the RAGE 82S allele displayed enhanced binding and cytokine/MMP generation following ligation by a prototypic S100/calgranulin compared with cells expressing the RAGE 82G allele. In human subjects, a case-control study demonstrated an increased prevalence of the 82S allele in patients with RA compared with control subjects. These data suggest that RAGE 82S upregulates the inflammatory response upon engagement of S100/calgranulins, and, thereby, may contribute to enhanced proinflammatory mechanisms in immune/inflammatory diseases.


Subject(s)
Arthritis, Rheumatoid/genetics , Polymorphism, Genetic , Receptors, Immunologic/genetics , Alleles , Animals , Arthritis, Experimental/immunology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , CHO Cells , Cricetinae , Humans , Leukocyte L1 Antigen Complex/genetics , Leukocyte L1 Antigen Complex/metabolism , Male , Mice , Mice, Inbred DBA , Receptor for Advanced Glycation End Products , Receptors, Immunologic/metabolism
6.
Surg Endosc ; 16(1): 22-4, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11961598

ABSTRACT

INTRODUCTION: Current investigational models of murine colitis and colon cancer necessitate sacrifice of animals in order to obtain colonic tissue. The purpose of this study was to develop a safe method of murine colonoscopy that would allow serial evaluation and mucosal biopsies of the same animal. METHODS: Nine mice (two C3H, two C57/BL6, and five IL-10 deficient) were studied a total of four times each over 4 weeks. Three mice [APC (Min +/-)] were examined three times each. Mice were gavaged with 1 cc of a polyethylene glycol solution on the day prior to colonoscopy. Solid chow was withheld and the mice were maintained on Pedialyte. Mice were anesthetized with ketamine and xylazine. A flexible pediatric cystoscope (2.1-mm diameter) with a single biopsy channel was introduced per anum, and the colon was gently insufflated with air to a mean pressure of less than 5 mmHg. Saline irrigation was used when necessary. A single biopsy was obtained from the rectosigmoid colon during each examination. RESULTS: A total of 46 examinations were carried out. One mouse died after being anesthesized for the fourth examination, and two mice [one IL-10 knockout and one APC (Min+/-)] died one day after the 3rd examination. No other complications were noted. The average length of insertion was 3 cm. Transillumination allowed for localization of the endoscope tip. Biopsies, although quite small, were sufficient for pathologic evaluation and diagnosis. CONCLUSIONS: Murine colonoscopy is a safe and feasible technique. It permits consecutive visual and histopathological examinations, and it allows the investigator to monitor the response of the murine colon to experimental interventions.


Subject(s)
Colitis/pathology , Colonic Neoplasms/pathology , Colonoscopy/methods , Animals , Biopsy/instrumentation , Biopsy/methods , Disease Models, Animal , Intestinal Mucosa/pathology , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains
7.
Diabetes ; 50(12): 2792-808, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11723063

ABSTRACT

Activation of the transcription factor nuclear factor-kappaB (NF-kappaB) has been suggested to participate in chronic disorders, such as diabetes and its complications. In contrast to the short and transient activation of NF-kappaB in vitro, we observed a long-lasting sustained activation of NF-kappaB in the absence of decreased IkappaBalpha in mononuclear cells from patients with type 1 diabetes. This was associated with increased transcription of NF-kappaBp65. A comparable increase in NF-kappaBp65 antigen and mRNA was also observed in vascular endothelial cells of diabetic rats. As a mechanism, we propose that binding of ligands such as advanced glycosylation end products (AGEs), members of the S100 family, or amyloid-beta peptide (Abeta) to the transmembrane receptor for AGE (RAGE) results in protein synthesis-dependent sustained activation of NF-kappaB both in vitro and in vivo. Infusion of AGE-albumin into mice bearing a beta-globin reporter transgene under control of NF-kappaB also resulted in prolonged expression of the reporter transgene. In vitro studies showed that RAGE-expressing cells induced sustained translocation of NF-kappaB (p50/p65) from the cytoplasm into the nucleus for >1 week. Sustained NF-kappaB activation by ligands of RAGE was mediated by initial degradation of IkappaB proteins followed by new synthesis of NF-kappaBp65 mRNA and protein in the presence of newly synthesized IkappaBalpha and IkappaBbeta. These data demonstrate that ligands of RAGE can induce sustained activation of NF-kappaB as a result of increased levels of de novo synthesized NF-kappaBp65 overriding endogenous negative feedback mechanisms and thus might contribute to the persistent NF-kappaB activation observed in hyperglycemia and possibly other chronic diseases.


Subject(s)
Diabetes Mellitus, Type 1/metabolism , NF-kappa B/physiology , Adult , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/pharmacology , Animals , Cell Nucleus/metabolism , Cytoplasm/metabolism , DNA/metabolism , Endothelium, Vascular/metabolism , Feedback , Female , Glycation End Products, Advanced/metabolism , Glycation End Products, Advanced/pharmacology , Humans , I-kappa B Proteins/metabolism , Immunohistochemistry , Leukocytes, Mononuclear/metabolism , Male , Mice , Mice, Transgenic , Middle Aged , NF-kappa B/analysis , NF-kappa B/genetics , NF-kappa B/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Receptor for Advanced Glycation End Products , Receptors, Immunologic/metabolism , S100 Proteins/metabolism , Serum Albumin, Bovine/pharmacology , Transcription Factor RelA
9.
J Clin Invest ; 108(10): 1439-50, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11714735

ABSTRACT

A series of events initiated by glutamate-receptor interaction perturbs cellular homeostasis resulting in elevation of intracellular free calcium and cell death. Cells subject to such environmental change express stress proteins, which contribute importantly to maintenance of metabolic homeostasis and viability. We show that an inducible chaperone present in endoplasmic reticulum (ER), the 150-kDa oxygen-regulated protein (ORP150), is expressed both in the human brain after seizure attack and in mouse hippocampus after kainate administration. Using mice heterozygous for ORP150 deficiency, exposure to excitatory stimuli caused hippocampal neurons to display exaggerated elevation of cytosolic calcium accompanied by activation of mu-calpain and cathepsin B, as well as increased vulnerability to glutamate-induced cell death in vitro and decreased survival to kainate in vivo. In contrast, targeted neuronal overexpression of ORP150 suppressed each of these events and enhanced neuronal and animal survival in parallel with diminished seizure intensity. Studies using cultured hippocampal neurons showed that ORP150 regulates cytosolic free calcium and activation of proteolytic pathways causing cell death in neurons subject to excitatory stress. Our data underscore a possible role for ER stress in glutamate toxicity and pinpoint a key ER chaperone, ORP150, which contributes to the stress response critical for neuronal survival.


Subject(s)
Endoplasmic Reticulum/metabolism , Glutamic Acid/toxicity , Hippocampus/drug effects , Molecular Chaperones/metabolism , Neurons/drug effects , Proteins/metabolism , Animals , HSP70 Heat-Shock Proteins , Heterozygote , Hippocampus/cytology , Hippocampus/metabolism , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Molecular Chaperones/genetics , Neurons/metabolism , Proteins/genetics
11.
FASEB J ; 15(14): 2757-9, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11606484

ABSTRACT

Hypoxic induction of the early growth response-1 (Egr-1) transcription factor initiates proinflammatory and procoagulant gene expression. Orthotopic/isogeneic rat lung transplantation triggers Egr-1 expression and nuclear DNA binding activity corresponding to Egr-1, which leads to increased expression of downstream target genes such as interleukin-1b, tissue factor, and plasminogen activator inhibitor-1. The devastating functional consequences of Egr-1 up-regulation in this setting are prevented by treating donor lungs with a phosphorothioate antisense oligodeoxyribonucleotide directed against the Egr-1 translation initiation site, which blocks expression of Egr-1 and its gene targets. Post-transplant graft leukostasis, inflammation, and thrombosis are consequently diminished, with marked improvement in graft function and recipient survival. Blocking expression of a proximal transcription factor, which activates deleterious inflammatory and coagulant effector mechanisms, is an effective molecular strategy to improve organ preservation.


Subject(s)
DNA-Binding Proteins/physiology , Immediate-Early Proteins , Inflammation/physiopathology , Lung Transplantation , Thrombosis/physiopathology , Transcription Factors/physiology , Animals , Blotting, Northern , Blotting, Western , DNA, Antisense/pharmacology , DNA-Binding Proteins/genetics , Early Growth Response Protein 1 , Fibrin/drug effects , Fibrin/metabolism , Gene Expression , Gene Expression Regulation/drug effects , Graft Survival/drug effects , Graft Survival/physiology , Interleukin-1/genetics , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Signal Transduction , Thromboplastin/genetics , Transcription Factors/genetics
12.
Front Biosci ; 6: D1151-60, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11578972

ABSTRACT

Receptor for AGE (RAGE), a member of the immunoglobulin superfamily, was first identified as a specific cell surface interaction site for Advanced Glycation Endproducts, or AGEs. AGEs, the products of nonenzymatic glycation/oxidation of proteins/lipids, accumulate in natural aging and disorders such as diabetes, renal failure and amyloidoses. Interaction of AGEs with RAGE has been linked to chronic inflammatory and vascular dysfunction that characterizes the chronic complications of these disorders. Recent studies have indicated that RAGE is a multiligand receptor, serving as a specific cell surface, signal transducing receptor for amphoterin, a molecule with implications for neurite outgrowth in neuronal development and in tumor cell proliferation and spread. RAGE is also a receptor for amyloid-beta peptide, whose interaction with neuronal and microglial RAGE within the CNS is linked to sustained inflammation and neuronal toxicity and cell death. RAGE also serves as a signal-transducing receptor for EN-RAGEs, and related members of the S100/calgranulin family of proinflammatory cytokines; consequences of this interaction include initiation and propagation of inflammatory responses. Consistent with an important role for ligand-RAGE interaction in these settings, blockade of RAGE suppresses chronic cellular activation and dysfunction in murine models of diabetic complications, inflammation and tumor proliferation and metastasis. Taken together, an new paradigm is emerging which links RAGE, a gene encoded within the Major Histocompatibility Complex (MHC) Class III regions, to central host response mechanisms in homeostasis and chronic disease.


Subject(s)
Major Histocompatibility Complex/genetics , Receptors, Immunologic/metabolism , Animals , Chronic Disease , Diabetes Complications , Diabetic Angiopathies/etiology , Diabetic Angiopathies/metabolism , Glycation End Products, Advanced/metabolism , Homeostasis , Humans , Inflammation/metabolism , Receptor for Advanced Glycation End Products , Receptors, Immunologic/genetics
14.
Am J Pathol ; 159(2): 513-25, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11485910

ABSTRACT

Receptor for advanced glycation end-products (RAGE), and two of its ligands, AGE and EN-RAGEs (members of the S100/calgranulin family of pro-inflammatory cytokines), display enhanced expression in slowly resolving full-thickness excisional wounds developed in genetically diabetic db+/db+ mice. We tested the concept that blockade of RAGE, using soluble(s) RAGE, the extracellular ligand-binding domain of the receptor, would enhance wound closure in these animals. Administration of sRAGE accelerated the development of appropriately limited inflammatory cell infiltration and activation in wound foci. In parallel with accelerated wound closure at later times, blockade of RAGE suppressed levels of cytokines; tumor necrosis factor-alpha; interleukin-6; and matrix metalloproteinases-2, -3, and -9. In addition, generation of thick, well-vascularized granulation tissue was enhanced, in parallel with increased levels of platelet-derived growth factor-B and vascular endothelial growth factor. These findings identify a central role for RAGE in disordered wound healing associated with diabetes, and suggest that blockade of this receptor might represent a targeted strategy to restore effective wound repair in this disorder.


Subject(s)
Diabetes Mellitus, Type 1/physiopathology , Glycation End Products, Advanced/physiology , Receptors, Immunologic/physiology , Receptors, Immunologic/therapeutic use , Wound Healing/physiology , Wounds and Injuries/pathology , Animals , Becaplermin , Binding Sites , Cytokines/biosynthesis , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/pathology , Endothelial Growth Factors/metabolism , Gene Expression Regulation , Granuloma/pathology , Granuloma/physiopathology , Lymphokines/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Models, Biological , Neovascularization, Physiologic , Platelet-Derived Growth Factor/metabolism , Proto-Oncogene Proteins c-sis , Receptor for Advanced Glycation End Products , Receptors, Immunologic/antagonists & inhibitors , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Wound Healing/genetics , Wounds and Injuries/physiopathology
15.
Thromb Haemost ; 86(1): 334-45, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11487022

ABSTRACT

Tissue factor (TF), the major initiator of blood coagulation, serves as a regulator of angiogenesis, tumor growth and metastasis. In several models, TF expression mediates upregulation of the proangiogenic vasular endothelial growth factor (VEGF) that can directly act on endothelial cells to promote vessel formation. This occurs through ligand binding, activation of signaling cascades, signal transduction and alteration of growth factor expression and is mediated by both, coagulation-dependent and -independent pathways. Depending on the cell type and the biological settings, TF seems to affect cellular properties through (i) factor VIIa (FVIIa)-dependent proteolysis of factor Xa (FXa) and thrombin and subsequent activation of proteinase activated receptor (PAR) -1 and PAR-2, (ii) through direct FVIIa signaling and mitogen activated protein (MAP) kinase activation, that is conferred by a not yet identified receptor, (iii) through interaction of FVII(a) proteolytic activity and signaling of the cytoplasmic domain and (iv) through cytoplasmic signaling independent of ligand binding. The role of phosphorylation of the cytoplasmic domain and the pathways controlling phosphorylation of TF remain poorly understood.


Subject(s)
Neovascularization, Physiologic/drug effects , Thromboplastin/physiology , Animals , Blood Coagulation/drug effects , Hemostatics/pharmacology , Humans , Neovascularization, Pathologic , Thromboplastin/pharmacology
16.
Exp Neurol ; 171(1): 29-45, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11520119

ABSTRACT

Receptor-mediated interactions with amyloid beta-peptide (Abeta) could be important in the evolution of the inflammatory processes and cellular dysfunction that are prominent in Alzheimer's disease (AD) pathology. One candidate receptor is the receptor for advanced glycation endproducts (RAGE), which can bind Abeta and transduce signals leading to cellular activation. Data are presented showing a potential mechanism for Abeta activation of microglia that could be mediated by RAGE and macrophage colony-stimulating factor (M-CSF). Using brain tissue from AD and nondemented (ND) individuals, RAGE expression was shown to be present on microglia and neurons of the hippocampus, entorhinal cortex, and superior frontal gyrus. The presence of increased numbers of RAGE-immunoreactive microglia in AD led us to further analyze RAGE-related properties of these cells cultured from AD and ND brains. Direct addition of Abeta(1-42) to the microglia increased their expression of M-CSF. This effect was significantly greater in microglia derived from AD brains compared to those from ND brains. Increased M-CSF secretion was also demonstrated using a cell culture model of plaques whereby microglia were cultured in wells containing focal deposits of immobilized Abeta(1-42). In each case, the Abeta stimulation of M-CSF secretion was significantly blocked by treatment of cultures with anti-RAGE F(ab')2. Treatment of microglia with anti-RAGE F(ab')2 also inhibited the chemotactic response of microglia toward Abeta(1-42). Finally, incubation of microglia with M-CSF and Abeta increased expression of RAGE mRNA. These microglia also expressed M-CSF receptor mRNA. These data suggest a positive feedback loop in which Abeta-RAGE-mediated microglial activation enhances expression of M-CSF and RAGE, possibly initiating an ascending spiral of cellular activation.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Receptors, Immunologic/metabolism , Aged , Aged, 80 and over , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/pharmacology , Cells, Cultured , Chemotaxis/drug effects , Dose-Response Relationship, Drug , Entorhinal Cortex/metabolism , Entorhinal Cortex/pathology , Feedback/drug effects , Female , Frontal Lobe/metabolism , Frontal Lobe/pathology , Hippocampus/metabolism , Hippocampus/pathology , Humans , Immunoglobulin Fab Fragments/pharmacology , Immunohistochemistry , Macrophage Colony-Stimulating Factor/genetics , Macrophage Colony-Stimulating Factor/metabolism , Male , Microglia/drug effects , Microglia/metabolism , Microglia/pathology , Middle Aged , Neurons/metabolism , Neurons/pathology , Peptide Fragments/pharmacology , RNA, Messenger/metabolism , Receptor for Advanced Glycation End Products , Receptors, Immunologic/antagonists & inhibitors , Receptors, Immunologic/genetics , Signal Transduction
17.
J Clin Invest ; 108(1): 41-50, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11435456

ABSTRACT

Expression of angiogenic factors such as VEGF under conditions of hypoxia or other kinds of cell stress contributes to neovascularization during wound healing. The inducible endoplasmic reticulum chaperone oxygen-regulated protein 150 (ORP150) is expressed in human wounds along with VEGF. Colocalization of these two molecules was observed in macrophages in the neovasculature, suggesting a role of ORP150 in the promotion of angiogenesis. Local administration of ORP150 sense adenovirus to wounds of diabetic mice, a treatment that efficiently targeted this gene product to the macrophages of wound beds, increased VEGF antigen in wounds and accelerated repair and neovascularization. In cultured human macrophages, inhibition of ORP150 expression caused retention of VEGF antigen within the endoplasmic reticulum (ER), while overexpression of ORP150 promoted the secretion of VEGF into hypoxic culture supernatants. Taken together, these data suggest an important role for ORP150 in the setting of impaired wound repair and identify a key, inducible chaperone-like molecule in the ER. This novel facet of the angiogenic response may be amenable to therapeutic manipulation.


Subject(s)
Cell Hypoxia/physiology , Endothelial Growth Factors/physiology , Lymphokines/physiology , Molecular Chaperones/physiology , Neovascularization, Physiologic/physiology , Proteins/physiology , Transcription Factors , Adenoviridae/genetics , Animals , Cells, Cultured , Culture Media, Conditioned , DNA-Binding Proteins/physiology , Diabetes Complications , Diabetes Mellitus/genetics , Endoplasmic Reticulum/metabolism , Endothelial Growth Factors/biosynthesis , Endothelial Growth Factors/genetics , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Female , Fibroblast Growth Factor 2/physiology , Gene Expression Regulation/drug effects , Genetic Therapy , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , HSP70 Heat-Shock Proteins , Humans , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Lymphokines/biosynthesis , Lymphokines/genetics , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Neovascularization, Pathologic/physiopathology , Nuclear Proteins/physiology , Oxygen/pharmacology , Protein Transport , Proteins/genetics , RNA, Antisense/pharmacology , RNA, Messenger/metabolism , Rats , Recombinant Fusion Proteins/physiology , Single-Blind Method , Skin/blood supply , Skin/injuries , Transforming Growth Factor beta/physiology , Transforming Growth Factor beta1 , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , Wound Healing/physiology
18.
Arterioscler Thromb Vasc Biol ; 21(6): 905-10, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11397695

ABSTRACT

Advanced glycation end products (AGEs) and their cell surface receptor, RAGE, have been implicated in the pathogenesis of diabetic complications. Here, we studied the role of RAGE and expression of its proinflammatory ligands, EN-RAGEs (S100/calgranulins), in inflammatory events mediating cellular activation in diabetic tissue. Apolipoprotein E-null mice were rendered diabetic with streptozotocin at 6 weeks of age. Compared with nondiabetic aortas and kidneys, diabetic aortas and kidneys displayed increased expression of RAGE, EN-RAGEs, and 2 key markers of vascular inflammation, vascular cell adhesion molecule (VCAM)-1 and tissue factor. Administration of soluble RAGE, the extracellular domain of the receptor, or vehicle to diabetic mice for 6 weeks suppressed levels of VCAM-1 and tissue factor in the aorta, in parallel with decreased expression of RAGE and EN-RAGEs. Diabetic kidney demonstrated increased numbers of EN-RAGE-expressing inflammatory cells infiltrating the glomerulus and enhanced mRNA for transforming growth factor-beta, fibronectin, and alpha(1) (IV) collagen. In mice treated with soluble RAGE, the numbers of infiltrating inflammatory cells and mRNA levels for these glomerular cytokines and components of extracellular matrix were decreased. These data suggest that activation of RAGE primes cells targeted for perturbation in diabetic tissues by the induction of proinflammatory mediators.


Subject(s)
Apolipoproteins E/genetics , Diabetes Mellitus, Experimental/complications , Receptors, Immunologic/physiology , Thromboplastin/biosynthesis , Vasculitis/metabolism , Animals , Aorta/metabolism , Kidney/metabolism , Leukocyte L1 Antigen Complex , Male , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , NF-kappa B/metabolism , Neural Cell Adhesion Molecules/metabolism , Receptor for Advanced Glycation End Products , Vascular Cell Adhesion Molecule-1/metabolism , Vasculitis/complications
19.
Am J Pathol ; 158(5): 1685-94, 2001 May.
Article in English | MEDLINE | ID: mdl-11337366

ABSTRACT

RA301/Tra2beta, a sequence-specific RNA-binding protein, was first cloned as a stress molecule in re-oxygenated astrocytes. In human vascular tissues, we have found enhanced RA301/Tra2beta expression in coronary artery with intimal thickening, and atherosclerotic aorta. Balloon injury to the rat carotid artery induced RA301/Tra2beta transcripts followed by expression of the antigen, which was detected in medial and neointimal vascular smooth muscle cells (VSMCs). In cultured VSMCs, hypoxia/re-oxygenation caused induction of RA301/Tra2beta and was accompanied by cell proliferation, both of which were blocked by the addition of either diphenyl iodonium, a NADPH oxidase inhibitor, PD98059, a mitogen-activated protein kinase kinase inhibitor, or antisense oligonucleotide for RA301/Tra2beta. Consistent with a link between RA301/Tra2beta and cell proliferation, platelet-derived growth factor also induced expression of RA301/Tra2beta in cultured VSMCS: These data suggest a possible role for RA301/Tra2beta in the regulation of VSMC proliferation, especially in the setting of hypoxia/re-oxygenation-induced cell stress.


Subject(s)
Carotid Arteries/metabolism , Muscle, Smooth, Vascular/cytology , Nerve Tissue Proteins/genetics , RNA-Binding Proteins/genetics , Adolescent , Adult , Aged , Animals , Biphenyl Compounds/pharmacology , Carotid Arteries/pathology , Cell Division/drug effects , Cell Division/physiology , DNA, Antisense/pharmacology , Dose-Response Relationship, Drug , Female , Flavonoids/pharmacology , Gene Expression , Humans , Infant , Male , Middle Aged , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Nerve Tissue Proteins/physiology , Onium Compounds/pharmacology , Oxygen/pharmacology , RNA Splicing , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA-Binding Proteins/physiology , Rats , Rats, Sprague-Dawley , Serine-Arginine Splicing Factors , Superoxides/metabolism
20.
Cancer Res ; 61(10): 4206-13, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11358846

ABSTRACT

Expression of angiogenic factors such as vascular endothelial growth factor (VEGF) under conditions of cell stress involves both transcriptional and translational events, as well as an important role for inducible endoplasmic reticulum (ER) chaperones. Coexpression of VEGF and 150-kDa oxygen-regulated protein (ORP), a novel ER chaperone, in human glioblastoma suggested a link between angiogenesis and ORP150. C6 glioma cells stably transfected with ORP150 antisense displayed selectively reduced ORP150 expression. Tumors raised after inoculation of immunocompromised mice with ORP150 antisense C6 glioma transfectants demonstrated an initial phase of growth comparable to wild-type C6 glioma cells which was followed by marked regression within 8 days. Decreased density of platelet/endothelial cell adhesion molecule 1-positive structures within the tumor bed was consistent with reduced angiogenesis in C6 gliomas expressing ORP150 antisense, compared with tumors derived from C6 cells overexpressing ORP150 sense or vector controls. In vitro, inhibition of ORP150 expression decreased release of VEGF into culture supernatants; in ORP150 antisense transfectants, VEGF accumulated intracellularly within the ER. These findings demonstrate a critical role for the inducible ER chaperone ORP150 in tumor-mediated angiogenesis via processing of VEGF, and, thus, highlight a new facet of angiogenic mechanisms amenable to therapeutic manipulation in tumors.


Subject(s)
Endoplasmic Reticulum/metabolism , Neovascularization, Pathologic/metabolism , Proteins/physiology , Animals , Autoantibodies/biosynthesis , Autoantibodies/blood , Cell Division/physiology , Cell Hypoxia/physiology , DNA, Antisense/genetics , Endothelial Growth Factors/biosynthesis , Endothelial Growth Factors/metabolism , Glioblastoma/blood supply , Glioblastoma/immunology , Glioblastoma/metabolism , Golgi Apparatus/metabolism , HSP70 Heat-Shock Proteins , Humans , Lymphokines/biosynthesis , Lymphokines/metabolism , Mice , Neovascularization, Pathologic/immunology , Protein Biosynthesis , Protein Processing, Post-Translational/physiology , Proteins/genetics , Rats , Transfection , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL